VOL. XXXIX NO. 7 THE JOURNAL OF ANTIBIOTICS Four-week-old male ICR mice weighing 20 to 21 g, eight per group, were injected intraperitoneally with 2 to 77 times the 50 % lethal doses of the bacteria, suspended in 0.5 ml of saline containing 2.5 5 .0% mucin (Difco Laboratories). One hour later, the mice were given a single subcutaneous injection of serial two-fold-diluted doses of test antibiotics or their combinations. Surviving mice were recorded one week after infection. The 50%. effective doses (ED50s, milligram per mouse) and the 95 % confidence limits were determined by the LITCHFIELD and WILCOxoN method.
To assess the in vivo effect of the combination of the two agents, the fractional effective dose (FED) index was used as a substitute for the fractional inhibitory concentration (FIC) index'). The in vivo synergy was defined by FED index <0.5. A sign of inequality was ignored for the calculation of FED index.
Determination of Blood Levels and Half-lives in Rats Eight-week-old Wistar rats weighing 290~350 g (male, 3 to 5 in a group) were used. Aqueous solutions of SF-2103A (10 mg/ml) and cefoperazone or cephalothin (20 mg/ml) were co-administered subcutaneously in a volume of 0.29 -0.35 ml per rat.
Blood samples were obtained from the rats by cardiac puncture at 5, 15, 30, 60, 120, 180 and 240 minutes after dosing. The blood samples were diluted with phosphate-citrate buffer at pH 7.0 for assays.
SF-2103A was determined by the (3-lactamase-inhibitory assay, as described below. The minimum concentration for detection was 0.006,ug/ml. Neither cefoperazone nor cephalothin interfered in the assay because of high dilution of the sample solution. Cefoperazone and cephalothin were determined by the paper disc agar diffusion method using Bacillus subtilis ATCC 8193 as a test organism. The minimum concentration for determination was 0.2 µg/ml. SF-2103A showed no activity under the conditions employed. The biological half-lives (TI/2) and area under the curves (AUCs between time zero and time infinity) were calculated by applying a one-compartment model. The significance of the results was examined by analysis of covariance.
For the determination of comparative blood levels of SF-2103A, SF-2050B and ampicillin, three or four ICR male mice were used for each experiment. Bloods per group were pooled, and drug levels were determined by the i3-lactamase-inhibitory assay (SF-2103A and SF-2050B) or by the paper disc agar diffusion assay (ampicillin) using B. subtilis ATCC 8193.
Urinary Recovery of SF-2103A Under anesthesia with pentobarbital, the bladders of Wistar rats were cannulated with two polyethylene tubes for successive urine collection (30-60 minutes intervals). One minute before sampling, 1 ml of phosphate-citrate buffer (pH 7.0) was injected through a one tube with an injection syringe, and urine samples were recovered from bladder through the other tube. The samples were diluted with phosphate-citrate buffer for assays.
Determination of /3-Lactamase Inhibitor in Biological Fluids
(3-Lactamase-inhibitory Assay: A sample solution (25 µl) was added on paper discs each containing 0.4 jig of cephalothin, which were placed on the agar plates containing B. subtilis ATCC 8193 and the crude (3-lactamase prepared by ultra-sonication of P. vulgaris GN76/C-1 cells2). The inhibition zone due to cephalothin was proportional to the concentration of an inhibitor that protected the hydrolysis of cephalothin from the (3-lactamase.
High Performance Liquid Chromatography (HPLC) Assay: A mixture of sample solution (0.1 ml) and cold ethanol (0.1 ml) was shaken, the precipitated proteins were removed by the refrigerated centrifugation at 3,000 rpm for 5 minutes, and the supernatant (10 µl) was injected to a HPLC column.
The HPLC was carried out using a Waters 6000A pump and reverse phase C18 yBondapak Column (Waters Associates Ltd.) (4 x 250 mm). SF-2103A was detected at 270 nm by an Hitachi UV spectrometer. The column eluant was based on tetrabutylammonium phosphate (Waters Associates Ltd.) (10 ml) plus 0.1 M potassium dihydrogen phosphate buffer (pH 5.0) (490 ml) plus methanol (235 ml) and pumped at 1 ml/minute at 20°C. Under these conditions, a retention time of SF-2103A was about 8 minutes.
Determination of Degradation Half-lives in Tissue Homogenates and Serum Fresh kidney cortex, lung and liver tissues and blood serum were collected from Wistar rats and ICR mice. Each organ (1 g) was sliced into small pieces and homogenized in 3 ml of 0.05 M phosphate buffer (pH 7.0) with a Teflon Potter-Ervehjem homogenizer for 1-2 minutes. After refrigerated centrifugation at 3,000 rpm for 15 minutes, the supernatant was used for degradation study of the antibiotics.
A mixture of 0.2 ml of the supernatant and 0.8 ml of a solution of the appropriate antibiotic (25 ug/ml in 0.05 M phosphate buffer) was incubated at 37°C. Samples were removed at time 0 and at frequent intervals during incubation, and diluted with phosphate buffer for assays.
For degradation study in serum, a mixture of the fresh serum (0.9 ml) and a solution of the antibiotic (0.1 ml, 200 jig/ml in 0.2 M phosphate buffer at pH 7.0) was incubated at 37°C. Fresh serum other than those of rats and mice were obtained from Golden Syrian hamsters, guinea pigs, Beagle dogs, pigs (Yorkshire), Albino rabbits, monkeys (Macaca irus) and human (Japanese). A preliminary experiment was set up to establish the most effective dosing of two agents. Table   1 shows the effect of administration schedule in combination use of SF-2103A and cefotaxime. The test pathogen was P. vulgaris GN76/C-1, which is a strong producer of type Ic cephalosporinase.
Under the conditions that administration of either SF-2103A or cefotaxime alone was not effective, simultaneous administration of both agents combined in a ratio of 1: 2 was found effective when given in a single dose or divided into two equal doses, given with an interval of 1 hour. There was no essential difference between the two routes of administration, as long as the two agents were given simultaneously. However, separate administration of the two agents with an interval of 1 hour resulted in the loss of the in vivo activity. The same tendency was observed for the combination of sulbactam and cefotaxime. Accordingly, a bolus administration of the combination 1 hour after the challenge was used throughout the following in vivo experiments. VOL. XXXIX NO. 7 THE JOURNAL OF ANTIBIOTICS Table 2 summarizes the in vivo efficacy of the combinations of SF-2103A or sulbactam with cefotaxime or cefoperazone at various dose ratios against P. vulgaris GN76/C-1. While neither SF-2103A nor cefotaxime was effective as a single agent, their combinations showed marked in vivo synergy with FED <0.1. The ED50 values of CTX were reduced more than 35 times by the 1: 2 combination.
The ED,, values appeared constant over a wide range of combination ratios from 1: 2 to 1: 128, implying that the addition of SF-2103A to cefotaxime in less than 1 % of the component brought about a maximum effect on the in vivo activity of the latter.
The combination of sulbactam with cefotaxime also showed marked increase of the in vivo activity. However, judging from the FED indices, the effect was three to four-fold inferior to that of SF-2103A. Furthermore, the ED50 values involving sulbactam tended to rise as the combination ratio increased, in particular at 1: 128, indicating loss of the synergistic activity.
The combination of SF-2103A with cefoperazone also showed marked in vivo synergy showing FED of 0.14, although cefoperazone alone was not effective. The ED50 values and FED indices did not change by changing the ratio from 1: 2 to 1: 8. These in vivo results were roughly those expected from the synergistic MIC values. and cefazolin also showed synergistic activity in vivo when combined with SF-2103A. In contrast, latamoxef, cefminox and cefmetazole in combination with SF-2103A showed the same or lower activity as those they were as single agents, indicating additive effect (FED index, 0.67-1.32).
Against E. coil GN206, latamoxef in combination with SF-2103A showed the highest in vivo activity, probably reflecting the high activity of the former.
Except for cephalothin, all of the tested Table 5 shows a preliminary comparison of the blood levels in mice of SF-2103A, another carbapenem antibiotic (SF-2050B3)) which possesses the N-acetylated aminoethenylthio side chain at C-3, and ampicillin. SF-2103A showed after being administered alone (29+3.7 minutes sc; 28.3±3.7 minutes iv) was similar to that found when it was given in the combinations.
Thus, the co-administration of SF-2103A with cephalosporins had essentially no effect upon its pharmacokinetics. Absorption of SF-2103A after oral administration (10 mg/kg) in rats was poor, 2.9+ 0.5 %, relative to that after subcutaneous administration.
The urinary excretion of SF-2103A in rats is shown in Fig. 3 . On an average a 55.2% recovery was obtained in 4 hours after a single subcutaneous administration.
The excretion half-life (29.0± 1.8 minutes) was close to the elimination half-life calculated from blood. 
Discussion
Since many of the organisms producing j3-lactamases were weakly pathogenic to mice, the strains available for in vivo experiments were rather limited. However, the therapeutic efficacy of SF-2103A in combination with eight cephalosporins was demonstrated against three Gram-negative organisms. The ED50 values shown by the SF-2103A combinations were generally two to four-fold lower than those of the corresponding combinations with sulbactam. Most notable is the high in vivo activity even at a combination ratio of 1: 128, suggesting a potent 13-lactamase-inhibitory property of SF-2103A.
Although SF-2103A itself showed moderate in vitro activity, the agent responsible for the in vivo antibacterial activity of the combinations is mainly the cephalosporin partner, since changes of the inhibitor: cephalosporin ratio of the combinations did not greatly affect their activity. This is in accord with the in vitro studies reported in the preceding paper2).
The high synergistic activity of SF-2103A can, at least partly, be ascribed to its good pharmacokinetic properties. While many of the carbapenem antibiotics gave low blood levels with rapid elimination6), SF-2103A gives blood levels and half-life comparable to those of the cephalosporin partners. Moreover, it showed a reasonable urinary recovery, which could be correlated with the stability against the kidney homogenate. This suggests that SF-2103A may be rather stable to the renal dihydropeptidase which has been reported to decompose other carbapenem antibiotics, giving a low urinary recovery of them7-10).
In this connection, it is notable that SF-2103A differs from other carbapenem antibiotics in that it contains the sulfonate group at C-3, which may be responsible for the fair stability of the compound in aqueous solution, serum and tissue homogenates. The sulfate ester group at C-8 may contribute to the N-lactamase inhibitory activity, since sulfate esters were more inhibitory than the corresponding hydroxy compounds in the olivanic acids') and C-19393 series11).
As far as the authors are aware of, there has been no previous report on the in vivo efficacy of carbapenem antibiotics as (3-lactamase inhibitors. This work appears to be the first examples of in vivo synergy between a carbapenem antibiotic and cephalosporins. VOL. XXXIX NO. 7
